Thermo Fisher Scientific Inc. $TMO Shares Sold by Corient Private Wealth LP

Corient Private Wealth LP cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 707,412 shares of the medical research company’s stock after selling 124,657 shares during the quarter. Corient Private Wealth LP’s holdings in Thermo Fisher Scientific were worth $354,690,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of TMO. Bank OZK acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $1,096,000. Ausdal Financial Partners Inc. purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $456,000. North Dakota State Investment Board acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $7,505,000. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. Finally, German American Bancorp Inc. acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth $4,920,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at $13,927,815. This represents a 1.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 73,768 shares of company stock worth $44,122,820. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research reports. Royal Bank Of Canada boosted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective for the company. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. CLSA started coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 target price on the stock. Finally, BMO Capital Markets downgraded Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $624.64.

Thermo Fisher Scientific Trading Down 0.3%

TMO stock opened at $603.80 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market cap of $223.26 billion, a P/E ratio of 32.48, a PEG ratio of 2.53 and a beta of 0.85. The company’s 50-day simple moving average is $578.63 and its 200-day simple moving average is $517.89.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.